$13.64
+0.25 (+1.87%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MDWD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
12 interventional · 2 observational · 1 expanded access · 2 with posted results
Held by 4 tracked-famous managers (Point72 Asset Management, L.P., CITADEL ADVISORS LLC, AQR CAPITAL MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 24.2 days to cover (settled 2026-07-31) · insider 90d: 6 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| An Open Label, Single Treatment, Single Arm, Multiple Dose Phase-2 Study to Evaluate the Pharmacokinetics, Safety, and Clinical Performance of EscharEx (EX-03) in Participants With Venous Leg UlcersNCT07692178PK EvaluationOpen-label · Treatment | Phase 2 | Not yet recruiting | Drug: EX-03 | Venous Leg Ulcer (VLU) | 20 | Aug 2028 | ≤ 743 d | 2026-07-09 |
| Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg UlcersNCT06690177Incidence (number of patients) of target wound related AEs throughout the trialRandomized · Quadruple-masked · Treatment | Phase 2 | Not yet recruiting | Drug: EscharEx (EX-03), Placebo (Gel vehicle) | Venus Leg Ulcers | 45 | 2027-12-30 | in 498 d | 2024-11-15 |
| A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)NCT06568627Incidence of complete debridement, clinically (visually) assessed after each applicationRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: EscharEx (EX-03), Placebo (Gel vehicle) | Venous Leg Ulcer (VLU) | 216 | Dec 2026 | ≤ 134 d | 2026-04-02 |
| A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell CarcinomaNCT05157763Incidence and severity of treatment-emergent AEs (TEAEs) and serious TEAEs (STEAEs).Open-label · Treatment | Phase 1/2 | Recruiting | Drug: EscharEx 5% (EX-02 formulation) | Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma | 32 | May 2022 | — | 2021-12-15 |
| A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg UlcersNCT04817228Incidence of complete debridementOpen-label · Treatment | Phase 2 | Completed | Drug: EscharEx (EX-02 formulation) | Venous Leg Ulcer, Diabetic Foot Ulcer | 12 | 2022-05-06actual | — | 2022-07-26 |
| A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg UlcersNCT03588130Incidence of complete debridement in EX-02 vs. Gel Vehicle arms, scored dichotomously (yes/no), clinically assessedRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC) | Venous Leg Ulcer | 120 | 2021-12-07actual | — | 2022-11-14 |
| A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of CareNCT02278718results2024-09-27Time to Complete Eschar Removal (in Days)Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: NexoBrid · Procedure: Standard of Care | Thermal Burns | 145 | Apr 2021actual | — | 2024-09-27 |
| A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal BurnsNCT02148705results2023-06-27Primary Endpoint: Number of Participants With Complete Eschar Removal.Randomized · Single-masked · TreatmentStudy Protocol: Protocol version 11 ↗ · Study Protocol: Protocol Version 9 ↗ · Study Protocol: Protocol Version 8 ↗ · Statistical Analysis Plan: Statistical Analysis Plan Protocol V11 V3amendment 02 ↗ · Statistical Analysis Plan: Statistical Analysis Plan Protocol V11 V3amendment 01 ↗ · Statistical Analysis Plan: Statistical Analysis Plan Protocol V11 V3 ↗ · Statistical Analysis Plan: Statistical Analysis Plan Protocol V11 V2amendment 01 ↗ · Statistical Analysis Plan: Statistical Analysis Plan Protocol V11 V2 ↗ | Phase 3 | Completed | Drug: NexoBrid, Gel Vehicle · Procedure: Standard of Care (SOC) | Thermal Burns | 175 | 2018-06-12actual | — | 2024-07-10 |
| Efficacy and Safety Study of EscharEx to Treat (Debride) Hard to Heal WoundsNCT02020746Incidence of complete debridement (non-viable tissue removal) at the end of the debridement period assessed by the blinded assessor by clinical evaluation.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: EscharEx, Gel Vehicle | Hard to Heal Wounds, Venous Leg Ulcers, Diabetic Lower Extremity Ulcers, Traumatic/ Post Operative Wounds | 111 | 2017-12-05actual | — | 2018-08-31 |
| Feasibility Study: Enzymatic Debridement in Patients With Partial Thickness BurnsNCT00898521The primary endpoint is safety as measured by: 1. Systemic an local adverse events, 2. Changes in vital signs and laboratory tests, 3. Time to wound closure.Open-label · Treatment | Phase 2 | Completed | Drug: DGD | Burn | 36 | 2015-12-02actual | — | 2021-09-09 |
| A Study, Performed in Subjects With Post Traumatic-post Surgical ,Venus Insufficiency and Diabetic Hard to Heal/Chronic Wounds, to Evaluate the Safety and Efficacy of PolyHeal-2 Versus PolyHeal in Once Daily RegimenNCT01679678Achievement of at least (≥)75% viable granulation tissue (grade 7 or 8 on the granulometer scale) after 4 weeks of study treatment (active phase)Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Business considerations | Device: PolyHeal 2, Polyheal | Surgical Wound Dehiscence | 15 | Aug 2014actual | — | 2016-03-30 |
| Functionality Assessments in Patients (Adults and Children) Following Treatment With Debrase Compared to Standard of CareNCT01800981observationalFunctionality evaluation using self reported questionnaires and ROM measurements | — | Unknown status | — | Burns, Upper Extremity, Burns, Lower Extremity | 53 | Jul 2013 | — | 2013-02-28 |
| Long Term Follow up of Scars Formation and Quality of Life Assessment StudyNCT01350700observational1. Scar assessment of target wounds that have been treated by Debrase or SOC during MW2004-11-02 using Modified Vancouver Scar Scale (MVSS) | — | Completed | Other: Scars assessment & QOL | Scars Formation, Quality of Life | 148 | Nov 2011actual | — | 2017-11-01 |
| Enzymatic Debridement in Burns Patients: A Comparison to Standard of CareNCT00324311Co-primary: % treated wound excised (by tangential/minor/Versajet excision) or dermabrasion, in first surgery, of deep partial woundsRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: DGD | Burn | 182 | Oct 2009actual | — | 2011-05-10 |
| Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn InjuriesNCT04040660expanded access | — | Approved for marketing | Drug: NexoBrid | Thermal Burn | — | — | — | 2024-08-30 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19